Ophthotech Corp. has acquired Inception 4 Inc. and its small molecule inhibitors of HtrA1, which are under development for the treatment of a range of retinal diseases, the company announced in a press release.
Ophthotech obtained $6.1 million in cash through the acquisition of Inception 4, which is backed by Versant Ventures. In addition, Ophthotech agreed to issue approximately 5.2 million shares of Inception 4, and Versant Ventures will own approximately 12.5% of Ophthotech’s outstanding common stock shares.
“We are thrilled to welcome Versant Ventures as a major shareholder
Uncategorized